Xena,
It could. On the other hand, Missling seemed to indicate on CC yesterday that he would like to get this (Blarc) to market asap - they even have a marketing team working on a company chosen commercial name for the drug - great!!
That being said, no matter how long the AD trial takes, if/when approval for Rett or PDD - off label use will take place. This is another great reason for the MOA paper - it will establish that Blarc is versatile across a much broader spectrum of indications and the method and extent to which it would have a strong impact on these and therefore it would read like a “Merck Manual” of drugs and their prescribing for pertinent indications. All imo.
Bio
News 
Market Data 
Discover 
